The GCP Committee is composed of representatives of the Association of Research-Based Pharmaceutical Companies (AİFD) members who conduct clinical research in our country. The mission of the Committee is to foster an increase in the number of clinical research studies in our country that thoroughly abide by the principles of Good Clinical Practices set forth as an international parameter in this area. The vision of the Committee may be summarized as contributing to an increase in investment poured into clinical research studies and the quality of practices to a level comparable in European countries and to a heightened awareness in our country regarding this matter.
Although a steadily increasing number of clinical research studies is being successfully conducted in our country, there still remain certain unresolved problems such as the need for legislation that is concordant with the European Union, lengthy approval processes from the Ethics Council and system inadequacies for payments to research teams and research centers. In order to address these issues, sub-committees such as Payments, Ethics Committees, Regulations and Observational Studies have been formed under the aegis of the Committee and these sub-committees continue to carry out their work in order to reach a solution.